Market Overview of Swine and Avian Influenza Research and Detailed Forecast

iCrowdNewswire – Dec 7, 2017

Pune, India, 7th December 2017: WiseGuyReports announced addition of new report, titled “Swine and Avian Influenza Drug Development Pipeline Review, 2017”.               

 

Summary

This report provides an overview of the Swine and Avian Influenza pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for influenza A virus, subtypes H5N1 and H1N1, and features dormant and discontinued projects.

H5N1 is a type of influenza virus that causes a highly infectious, severe respiratory disease in birds called avian influenza. This virus can spread to humans. There are a total of 63 products in development for this indication, by 47 companies and six academic institutions.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/2593446-swine-and-avian-influenza-drug-development-pipeline-review-2017

H1N1 Infection also called as swine flu is a new kind of flu in humans. It’s caused by the contagious H1N1 influenza virus. There are a total of 99 products in development for this indication, by 67 companies and 14 academic institutions.

In both types of influenza, the most common molecular target being studied is hemagglutinin, by a considerable margin. However, a number of both human and viral proteins are also under active development.

Scope

– Which companies are the most active within each pipeline?

– Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?

– To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?

– What are the most important R&D milestones and data publications to have happened in this disease area?

Reasons to buy

– Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication

– Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each

– Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these

– Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Table of Content: Key Points

1 Table of Contents 4

    1.1 List of Tables 5

    1.2 List of Figures 7

2 Introduction 8

    2.1 Swine and Avian Influenza Report Coverage 8

    2.2 Influenza A Virus, H5N1 Subtype Infections – Overview 8

    2.3 Influenza A Virus, H1N1 Subtype Infections – Overview 8

3 Therapeutics Development 9

    3.1 Influenza A Virus, H5N1 Subtype Infections 9

    3.2 Influenza A Virus, H1N1 Subtype Infections 18

4 Therapeutics Assessment 30

    4.1 Influenza A Virus, H5N1 Subtype Infections 30

    4.2 Influenza A Virus, H1N1 Subtype Infections 36

5 Companies Involved in Therapeutics Development 43

    5.1 Influenza A Virus, H5N1 Subtype Infections 43

    5.2 Influenza A Virus, H1N1 Subtype Infections 58

6 Dormant Projects 81

    6.1 Influenza A Virus, H5N1 Subtype Infections 81

    6.2 Influenza A Virus, H1N1 Subtype Infections 86

7 Discontinued Products 90

    7.1 Influenza A Virus, H5N1 Subtype Infections 90

    7.2 Influenza A Virus, H1N1 Subtype Infections 90

8 Product Development Milestones 91

    8.1 Influenza A Virus, H5N1 Subtype Infections 91

    8.2 Influenza A Virus, H1N1 Subtype Infections 103

…Continued                            

 

ACCESS REPORT @ https://www.wiseguyreports.com/reports/2593446-swine-and-avian-influenza-drug-development-pipeline-review-2017             

                                 

Contact Info:                                                         

NORAH TRENT                                                      

[email protected]             

Ph: +1-646-845-9349 (US)                          

Ph: +44 208 133 9349 (UK)                                                   

                                                                             

Get in touch:                                                         

LinkedIn: www.linkedin.com/company/4828928

Twitter: https://twitter.com/WiseGuyReports                                                                  

Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts